Subscribe to RSS
DOI: 10.1055/s-2006-931478
Massive Creatine Kinase Elevations with Quetiapine: Report of Two Cases
A Case ReportPublication History
Received: 6.7.2004
Revised: 17.9.2005
Accepted: 11.10.2005
Publication Date:
02 February 2006 (online)
![](https://www.thieme-connect.de/media/pharmaco/200601/lookinside/thumbnails/10.1055-s-2006-931478-1.jpg)
Massive elevations of serum creatine kinase (CK) can occur in a significant number of patients treated with neuroleptics in the absence of neuroleptic malignant syndrome (NMS). We report two cases of CK-elevations associated with quetiapine treatment, which disappeared after drug discontinuation. To our knowledge, case number one is the first case of quetiapine-induced CK elevation in a neuroleptic-naïve patient. We thus suggest CK assessment when myalgia occurs with neuroleptic treatment.
References
- 1 Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000; 85 129-135
- 2 Boot E, de Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology. 2000; 150 347-348
- 3 Devarajan S, Dursum S M. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms. Psychopharmacology. 2000; 152 122
- 4 Holtmann M, Meyer A E, Pitzer M, Schmidt M H. Risperidone-induced marked elevation of serum creatine kinase in adolescence. A case report. Pharmacopsychiatry. 2003; 36 317-318
- 5 Keshavan M S, Stecker J, Kambhampati R K. Creatine kinase elevations with clozapine. Br J Psychiatry. 1994; 164 118-120
- 6 Kirson J L, McQuistion H L, Pierce D W. Severe elevations in serum creatine kinase associated with clozapine. J Clin Psychopharmacol. 1995; 15 287-288
- 7 Marcus E L, Vass A, Zislin J. Marked elevation of creatine kinase associated with olanzapine therapy. Ann Pharmacother. 1999; 33 697-700
- 8 Meltzer H Y. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology. 2000; 150 349-350
- 9 Meltzer H Y, Cola P A, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 1996; 15 395-405
- 10 Reznik I, Volchek L, Mester R, Kotler M, Sarova-Pinhas I, Spivak B, Weizman A. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacology. 2000; 23 276-280
- 11 Rosebraugh C J, Flockhart D A, Yasuda S U, Woosley R L. Olanzapine-induced rhabdomyolysis. Ann Pharmacother. 2001; 35 020-1023
- 12 Roth D, Alarcon F J, Fernandez J A, Preston R A, Bourgoignie J J. Acute rhabdomyolysis associated with cocaine intoxication. N Engl J Med. 1988; 319 673-677
- 13 Sass H, Houben I. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. [dt.] Göttingen; Hogrefe 1996: p 832
- 14 Scelsa S N, Simpson D M, McQuistion H L, Fineman A, Ault K, Reichler B. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology. 1996; 47 1518-1523
- 15 Sieb J P, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve. 2002; 27 142-156
Maria C. Jockers-Scherübl, MD
Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie
Charité - Universitätsmedizin Berlin
Campus Benjamin Franklin
Eschenallee 3
14050 Berlin
Germany
Phone: +49 30 8445 8707
Fax: +49 30 8445 8341
Email: maria.jockers@charite.de